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Two-Year Angiographic and Intravascular Ultrasound
Follow-Up After Implantation of Sirolimus-Eluting Stents in
Human Coronary Arteries
J. Eduardo Sousa, MD, PhD; Marco A. Costa, MD, PhD; Amanda G.M.R. Sousa, MD, PhD;
Alexandre C. Abizaid, MD, PhD; Ana C. Seixas, MD; Andrea S. Abizaid, MD;
Fausto Feres, MD, PhD; Luiz A. Mattos, MD, PhD; Robert Falotico, PhD; Judith Jaeger, BA;
Jeffrey J. Popma, MD; Patrick W. Serruys, MD, PhD
Background—The safety and efficacy of sirolimus-eluting stenting have been demonstrated, but the outcome of patients
treated with this novel technology beyond the first year remains unknown. We sought to evaluate the angiographic,
intravascular ultrasound (IVUS), and clinical outcomes of patients treated with sirolimus-eluting stents 2 years after
implantation.
Methods and Results—This study included 30 patients treated with sirolimus-eluting Bx Velocity stenting (slow release
[SR], n15, and fast release [FR], n15) in São Paulo, Brazil. Twenty-eight patients underwent 2-year angiographic
and IVUS follow-up. No deaths occurred during the study period. In-stent late loss was slightly greater in the FR group
(0.280.4 mm) than in the SR group (0.090.23 mm, P0.007). No patient had in-stent restenosis. At 2-year
follow-up, only 1 patient (FR group) had a 52% diameter stenosis within the lesion segment, which required repeat
revascularization. The target-vessel revascularization rate for the entire cohort was 10% (3/30) at 2 years. All other
patients had 35% diameter stenosis. Angiographic lumen loss at the stent edges was also minimal (in-lesion late loss
was 0.330.42 mm [FR] and 0.130.29 mm [SR]). In-stent neointimal hyperplasia volume, as detected by IVUS,
remained minimal after 2 years (FR 9.909 mm3 and SR10.359.3 mm3).
Conclusions—This study demonstrates the safety and efficacy of sirolimus-eluting Bx Velocity stents 2 years after
implantation in humans. In-stent lumen dimensions remained essentially unchanged at 2-year follow-up in the 2 groups,
although angiographic lumen loss was slightly higher in the FR group. Restenosis “catch-up” was not found in our
patient population. (Circulation. 2003;107:381-383.)
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A new generation of drug-eluting coronary stents de-signed to limit restenosis has been developed recently.
The clinical success of these novel technologies will depend
on a complex interaction between stent, coating matrix, drug,
and the vessel wall. Stents coated with sirolimus, a natural
macrocyclic lactone with immunosuppressive and anti-
inflammatory action, represented the first successful attempt
to abolish restenosis in human coronary arteries.1–3 A virtual
absence of neointimal proliferation was observed 1 year after
implantation of sirolimus-eluting Bx Velocity stents in a pilot
study.2 Subsequently, the RAVEL (a RAndomized compari-
son of a sirolimus-eluting Bx VELocity stent with a standard
stent for coronary revascularization) investigators reported an
absence of both angiographic restenosis at 6 months and
target-lesion revascularization 1 year after the implantation of
sirolimus-eluting stents in a multicenter randomized trial.3
Although encouraging, potential late side effects of these
drug-eluting coronary stents may pose limitations. Lessons
from intracoronary brachytherapy include the development of
late thrombosis and neointimal proliferation that may occur
beyond the first year after treatment.4–6 In the present study,
we evaluated the clinical, angiographic, and intravascular
ultrasound (IVUS) outcomes of the first series of patients
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Fifteen patients received a fast-release (FR) formulation (15-day
drug release), and 15 received a slow-release (SR) formulation
(28-day drug release). All stents were 18 mm long and 3.0 to
3.5 mm in diameter. The stent procedure and drug-elution kinetics
have been described previously.1,2 Patients received aspirin (325
mg/d, indefinitely) started at least 12 hours before the procedure and
a 300-mg loading dose of clopidogrel immediately after stent
implantation and then clopidogrel 75 mg/d for 60 days. The Medical
Ethics Committee at Institute Dante Pazzanese approved the proto-
col, and every patient provided informed consent.
Quantitative Measurements
Quantitative coronary angiography and IVUS imaging were per-
formed after bolus infusion of intracoronary nitrates as described
previously. IVUS images were acquired by motorized pullback at a
constant speed of 0.5 mm/s. Quantitative angiographic and volumet-
ric IVUS analyses were performed by independent core laboratories
(Brigham and Women’s Hospital, Boston, Mass, and Cardialysis
BV, Rotterdam, the Netherlands, respectively). Validation of volu-
metric IVUS quantification has been described elsewhere.7 Two
coronary segments were subjected to quantitative angiography: (1)
in-stent and (2) in-lesion segments. The in-stent analysis encom-
passed only the 18-mm-long segment covered by the stent. The
in-lesion segment was defined as the stent plus 5 mm proximal and
5 mm distal to the edge or the nearest side branch. In-stent and
in-lesion restenosis was defined as 50% diameter stenosis (DS) at
follow-up located within the stent and target lesion, respectively.
Minimal lumen diameter (MLD) and %DS were measured for each
segment. In-lesion and in-stent late lumen loss (LL) were calculated
as postprocedure MLD minus 2-year follow-up MLD. LL between 1-
and 2-year follow-up was also calculated. Intimal hyperplasia vol-
ume was calculated as stent volume minus luminal volume. Percent
intimal hyperplasia was defined as intimal hyperplasia volume
divided by stent volume.
Statistical Analysis
Continuous variables are expressed as meanSD. Comparisons
between postintervention and follow-up measurements were per-
formed with a 2-tailed paired t test. Comparisons between groups
were performed with an unpaired Student’s t test. A probability value
0.05 was considered statistically significant.
Results
Both patient groups (FR and SR) had similar baseline
characteristics, as reported previously.1,2 Angiographic and
IVUS imaging were performed in 28 patients at 2-year
follow-up. No deaths occurred during the study period. As
reported previously,2 1 patient had myocardial infarction
secondary to target-vessel occlusion at 14-month follow-up,
which precluded further angiographic assessment. Another
patient developed pneumonia the week preceding the sched-
uled 2-year follow-up angiogram, and angiographic assess-
ment was therefore deferred.
The majority of patients (71% in the FR and 85% in the SR
group) had 0.5-mm LL (Figure 1) 2 years after stent
implantation. Although the average in-lesion LL was not
significantly different between the FR (0.330.42 mm) and
SR (0.130.29 mm) groups, in-stent LL was statistically
lower in the SR population (0.090.24 versus
0.280.41 mm, P0.007). No patient in the SR group had
0.2 mm in-stent LL. In-lesion MLD remained essentially
unchanged between 1 and 2 years in the FR group and
actually increased in the SR group (P0.001 for MLD at 1
year versus MLD at 2 years; Figure 2). In-lesion and in-stent
MLD were greater in the SR group than in the FR group
(Figure 2) at 2-year follow-up. Plaque volume by IVUS was
9.909 mm3 (FR) and 10.359.3 mm3 (SR), whereas the
percent intimal hyperplasia along the entire length of the stent
was only 6.35.5% in the FR group and 7.57.3% in the SR
group.
No patient had in-stent restenosis (50% DS). Only 1
patient (FR group) had a 52% DS proximal to the stent. He
was successfully treated with the implantation of a sirolimus-
eluting stent at 24 months. Another patient developed an
ostial lesion in the left circunflex coronary artery and under-
went coronary bypass surgery (target-vessel revasculariza-
tion) 24.5 months after the index procedure. The sirolimus-
eluting stent implanted in the midportion of the left circunflex
coronary artery was patent, with minimal neointimal prolif-
eration. Two patients underwent percutaneous interventions
in vessels other than the target coronary (nontarget-vessel
revascularization) after 24 months.
Discussion
The present study demonstrates the long-term safety and
efficacy of the sirolimus-eluting stent 2 years after implanta-
tion. There were no deaths, and only 1 patient developed
in-lesion restenosis by angiography. After 2 years, no patient
developed in-stent restenosis, and 90% of patients were free
of repeat target-vessel revascularization. Neointimal prolifer-
ation remained minimal at 2 years after stent implantation.
Sirolimus acts specifically on the late G1 phase of the cell
cycle, unlike ionizing radiation. Because of its early action on
Figure 1. Cumulative distribution curves of in-stent and in-lesion
LL in FR and SR groups after 2 years’ follow-up.
Figure 2. Temporal changes in angiographic in-lesion and
in-stent MLD.
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the cell cycle, sirolimus may block cellular proliferation
without inducing cell death and necrosis, with its potential
late vascular sequelae.8,9 In addition, sirolimus has been
shown to stimulate apoptosis and reduce inflammation.10,11
The striking efficacy and safety 2 years after stent implanta-
tion in the present study are likely due to these unique cellular
effects of sirolimus.
Previous investigations have shown the long-term safety of
bare metallic stents.12–14 In serial angiographic studies, in-
stent lumen diameter was shown to be similar between 6
months and 1 year and even improved slightly 3 years after
initial stent implantation.12 In the present study, similar
angiographic findings were observed. However, only mini-
mal lumen reduction was observed in the first 4 months.1
Furthermore, unlike previous studies, the 2-year lumen diam-
eters of most patients remained virtually unchanged from the
initial postimplantation measurements (Figures 1 and 2).5,6,15
There was no (early or late) stent malapposition or flow
behind the stent struts depicted by IVUS. It remains to be
determined whether arterial spasm immediately after the
procedure that disappeared at 2-year follow-up explains the
increase in MLD observed by quantitative coronary angiog-
raphy in some patients.
Although both types of drug-eluting stent formulation were
safe and effective at 2-year follow-up, the SR stents had a
slightly better angiographic outcome than the FR stents. The
amount of drug, type of polymer, and size of stents used were
identical in the 2 groups. The only differences between the 2
groups were the extra layer of polymer coating in the SR
formulation and the drug-release profile of each stent formu-
lation (28-day drug release in the SR versus 14 days in the
FR formulation). Whether a prolonged drug release confers
longer and better antirestenosis protection remains to be
determined. Neointimal hyperplasia volume as determined by
IVUS was similar between groups. Furthermore, the major
studies to date with the sirolimus-eluting stent (eg, the
RAVEL and SIRIUS [a multicenter randomized double-blind
study of the SIRolImUS-eluting Bx Velocity stent in the
treatment of patients with de novo coronary artery lesions]
trials) have all used the SR formulation.
Among the patients who underwent 2-year follow-up
angiography, 1 patient had a borderline (52% DS) in-lesion
stenosis. It is difficult to determine whether this lesion was
secondary to restenosis or plaque progression. Regardless of
the underlying mechanism, this case may underscore the
importance of complete stent coverage of the treated lesion or
injured segments when drug-eluting stents are implanted. The
protocol in the present study allowed the implantation of only
one 18-mm-long stent in each patient, which may have
limited our ability to completely cover the entire atheroscle-
rotic plaque in some patients.
In conclusion, the present study demonstrates the 2-year
safety and efficacy of sirolimus-eluting stents for inhibiting
restenosis after percutaneous coronary interventions. These
long-term angiographic and IVUS results 2 years after the
index procedure lend further credence to the recently reported
absence of restenosis after 1 year among patients treated with
sirolimus-eluting stents in the multicenter randomized
RAVEL study.3 Although the vexing problem of restenosis
after angioplasty may be largely solved by this new genera-
tion of drug-eluting stents, there is clearly a need for new
therapies to prevent the progression of atherosclerosis and
techniques to identify and treat non–flow-limiting vulnerable
plaques.
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